Enrollment in U.S. Pilot Study Evaluating Bioelectronic Device for Treatment of Rheumatoid Arthritis Completed

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

October 17, 2021

Enrollment in the U.S. Food and Drug Administration pilot Investigational Device Exemption (IDE) study evaluating its proprietary bioelectronic device to treat patients with drug-refractory rheumatoid arthritis (RA).

The primary purpose of this multi-center, randomized study is to evaluate the safety and tolerability of SetPoint’s proprietary device, which is surgically placed on the vagus nerve. The study includes 14 subjects who had failed or were intolerant to multiple, mechanistically different, biologic therapies. Initial feedback from neurosurgeons performing the implantation has been positive. The company anticipates data readout in the first quarter of 2019.

“While vagus nerve stimulation has demonstrated success in treating neurological conditions such as epilepsy for more than 20 years, this unique therapeutic approach is a compelling and exciting development for the treatment of chronic autoimmune diseases including rheumatoid arthritis,” said R. Mark Richardson, MD, Ph.D., Associate Professor of Neurological Surgery at University of Pittsburgh Medical Center and a surgical investigator in the study. “Implanting this miniaturized, integrated device directly on the vagus nerve was relatively straightforward, requiring only one small incision, and I look forward to the safety and tolerability results.”

SetPoint’s proprietary implant is approximately one inch long. Once surgically placed on the vagus nerve, the device is programmed to automatically deliver electrical doses on a preset schedule.

“Current therapies for rheumatoid arthritis are ineffective in a number of patients, have serious side effects, and are costly, so new treatment options are desperately needed for patients who do not respond adequately to drugs approved for the treatment of RA,” said David Sikes, MD, a rheumatologist at Florida Medical Clinic in Zephyrhills, Fla. and an investigator in the study. “The development of bioelectronic medicine could offer a completely novel treatment approach for managing our RA patients.”

“Physicians and their patients who have failed conventional therapy desperately need alternative approaches for the treatment of drug-refractory RA,” said David Chernoff, MD, Chief Medical Officer of SetPoint Medical. “We were highly gratified with the rapid enrollment in our study and look forward to presenting the results of the trial early next year.”

Editor’s Note: Tumeric Curcumin is used by many to help manage rheumatoid arthritis.

 

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.